{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"TCRT","limit":50},"count":50,"signals":[{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":40,"context":"ny delisting. We have identified a material weakness and failed to maintain an effective internal control environment, which may result in material misstatements of our financial statements or have a material adverse effect on our business or stock price. Our small molecule Obesity and Metabolic Disorders Program is in an early preclinical stage and faces significant risks and requires substantial additional capital. We","filed_date":"2026-03-31","accession":"0001193125-26-134720","full_text":"https://origin.rootz.global/static/filing/0001193125-26-134720.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"ing ascribed to such term in Section 3.1(p). “Liens” means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. “Material Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b). “Material Permits” shall have the meaning ascribed to such term in Section 3.1(n). “Per Share Purchase Pri","filed_date":"2025-06-26","accession":"0000950170-25-090202","full_text":"https://origin.rootz.global/static/filing/0000950170-25-090202.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":35,"context":"1, 2025 by the audit committee (the audit committee) of the board of directors of the Company (the Board) (Proposal 2); | | | 3. | To approve, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the proxy statement (Proposal 3); | | | 4. | To approve the Second amendment and restatement of the Companys amended and restated certificate of incorporation, as amended (our Char","filed_date":"2025-05-21","accession":"0001193125-25-123677","full_text":"https://origin.rootz.global/static/filing/0001193125-25-123677.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"rector, was appointed as a non-employee director in December 2023, prior to his appointment as interim Chief Executive Officer in January 2024. | | | Dale Curtis Hogue, Jr.Director | Mr. Hogue was appointed our interim Chief Executive Officer in January 2024 and a member of our Board in December 2023. Mr. Hogue has worked for over 20 years in various roles on both the buy- and sell-side covering biotechnology and pharmaceutical equities.","filed_date":"2025-04-30","accession":"0000950170-25-061207","full_text":"https://origin.rootz.global/static/filing/0000950170-25-061207.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":12,"context":"ecember 31, 2024, we had a net loss of $4.6 million, and, as of December 31, 2024, our accumulated deficit since inception in 2003 was $920.4 million. Although we are in the process of implementing a restructuring plan, or the Plan, whereby we are winding down our TCR-T Library Phase 1/2 Trial, other development programs and implemented a reduction in force, in order to reduce operating expenditures and net losses,","filed_date":"2025-03-31","accession":"0000950170-25-047758","full_text":"https://origin.rootz.global/static/filing/0000950170-25-047758.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":55,"context":"ing decision. We have identified a material weakness and failed to maintain an effective internal control environment, which may result in material misstatements of our financial statements or have a material adverse effect on our business or stock price. For our small molecule oral obesity program or should we resume development of our TCR-T product candidates, we may not be able to commercialize them, generate signifi","filed_date":"2025-03-31","accession":"0000950170-25-047758","full_text":"https://origin.rootz.global/static/filing/0000950170-25-047758.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"We may identify material weaknesses in the future or otherwise fail to maintain an effective internal controls system, which may result in material misstatements of our financial statements or have a material adverse effect on our business or stock price. The termination of our licenses and research and development agreement with the National Cancer Institute and Precigen could limit our ability to resume our clinical t","filed_date":"2024-11-14","accession":"0000950170-24-126793","full_text":"https://origin.rootz.global/static/filing/0000950170-24-126793.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"We may identify material weaknesses in the future or otherwise fail to maintain an effective internal controls system, which may result in material misstatements of our financial statements or have a material adverse effect on our business or stock price. The termination of our licenses and research and development agreement with the National Cancer Institute could limit our ability to resume our clinical trial or begin","filed_date":"2024-08-14","accession":"0000950170-24-097142","full_text":"https://origin.rootz.global/static/filing/0000950170-24-097142.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"We may identify material weaknesses in the future or otherwise fail to maintain an effective internal controls system, which may result in material misstatements of our financial statements or have a material adverse effect on our business or stock price. The recent termination of our licenses and research and development agreement with the National Cancer Institute could limit our ability to resume our clinical trial o","filed_date":"2024-05-15","accession":"0000950170-24-060075","full_text":"https://origin.rootz.global/static/filing/0000950170-24-060075.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":31,"context":"1, 2024 by the audit committee (the audit committee) of the board of directors of the Company (the Board) (Proposal 2); | | | 3. | To approve, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the proxy statement (Proposal 3); | | | 4. | To approve the amendment and restatement of the Companys second amended and restated certificate of incorporation, as amended (our Char","filed_date":"2024-04-26","accession":"0001193125-24-118247","full_text":"https://origin.rootz.global/static/filing/0001193125-24-118247.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":10,"context":"cember 31, 2023, we had a net loss of $35.1 million, and, as of December 31, 2023, our accumulated deficit since inception in 2003 was $915.8 million. Although we are in the process of implementing a restructuring plan, or the Plan, whereby we are winding down our TCR-T Library Phase 1/2 Trial, other development programs and implemented a reduction in force, in order to reduce operating expenditures and net losses,","filed_date":"2024-04-01","accession":"0000950170-24-038868","full_text":"https://origin.rootz.global/static/filing/0000950170-24-038868.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":53,"context":"We may identify material weaknesses in the future or otherwise fail to maintain an effective internal controls system, which may result in material misstatements of our financial statements or have a material adverse effect on our business or stock price. The recent termination of our licenses and research and development agreement with the National Cancer Institute could limit our ability to resume our clinical trial o","filed_date":"2024-04-01","accession":"0000950170-24-038868","full_text":"https://origin.rootz.global/static/filing/0000950170-24-038868.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":9,"context":"ive | | | 3,578 | | | | 3,282 | | | | 9,791 | | | | 10,217 | | | | Gain on lease modification | | | — | | | | — | | | | (245 | ) | | | (133 | ) | | | Restructuring costs | | | 419 | | | | — | | | | 419 | | | | — | | | | Property and equipment and right-of-use asset impairment | | | 1,011 | | | | — | | | | 1,011 | |","filed_date":"2023-11-14","accession":"0000950170-23-063354","full_text":"https://origin.rootz.global/static/filing/0000950170-23-063354.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"factors. As of September 30, 2023, based on information readily available, other than as described below, there are no material matters that, in the opinion of management, are likely to result in a material adverse effect on our financial position, results of operations or cash flows. KBI Biopharma Litigation On March 17, 2023, KBI Biopharma, Inc., or KBI, filed a complaint against us in the District Court of Harris","filed_date":"2023-11-14","accession":"0000950170-23-063354","full_text":"https://origin.rootz.global/static/filing/0000950170-23-063354.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"other factors. As of June 30, 2023, based on information readily available, other than as described below, there are no material matters that, in the opinion of management, are likely to result in a material adverse effect on our financial position, results of operations or cash flows. KBI Biopharma Litigation On March 17, 2023, KBI Biopharma, Inc., or KBI, filed a complaint against us in the District Court of Harris","filed_date":"2023-08-14","accession":"0000950170-23-042486","full_text":"https://origin.rootz.global/static/filing/0000950170-23-042486.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"t attention and resources and other factors. As of March 31, 2023, based on information readily available, there are no material matters that, in the opinion of management, are likely to result in a material adverse effect on our financial position, results of operations or cash flows. Item 1A. Risk Factors The following important factors could cause our actual business and financial results to differ materially from","filed_date":"2023-05-10","accession":"0000950170-23-020088","full_text":"https://origin.rootz.global/static/filing/0000950170-23-020088.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":40,"context":"1, 2023 by the audit committee (the audit committee) of the board of directors of the Company (the Board) (Proposal 2); | | | 3. | To approve, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the proxy statement (Proposal 3); | | | 4. | To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of our named executive off","filed_date":"2023-04-25","accession":"0001193125-23-115492","full_text":"https://origin.rootz.global/static/filing/0001193125-23-115492.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"ing whereas in TIL specificity typically arises from the endogenous TCR rather than an introduced immunoreceptor. 7 [Table of Contents](#toc_page) Background on TCRs Our strategy is to target the hallmark of genomic instability in cancer with TCRs. Genes in cancer cells can lead to the production of proteins, which are then processed by the cell into protein fragments known as peptides. These pepti","filed_date":"2023-03-07","accession":"0000950170-23-006377","full_text":"https://origin.rootz.global/static/filing/0000950170-23-006377.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"on of production or distribution, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a biological product may be approved for marketing in the United States generally involves the following: • completion of preclinical laboratory","filed_date":"2023-03-07","accession":"0000950170-23-006377","full_text":"https://origin.rootz.global/static/filing/0000950170-23-006377.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"tention and resources and other factors. As of September 30, 2022, based on information readily available, there are no material matters that, in the opinion of management, are likely to result in a material adverse effect on our financial position, results of operations or cash flows. Item 1A. Risk Factors The following important factors could cause our actual business and financial results to differ materially from","filed_date":"2022-11-14","accession":"0000950170-22-024695","full_text":"https://origin.rootz.global/static/filing/0000950170-22-024695.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"ntain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the COVID-19 pandemic could have a material adverse effect on the Company’s business, financial condition, results of operations and growth prospects. 2. Financings 2021 Loan and Security Agreement On August 6, 2021, the Company entered into a Loan a","filed_date":"2022-08-15","accession":"0000950170-22-017225","full_text":"https://origin.rootz.global/static/filing/0000950170-22-017225.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"ntain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the COVID-19 pandemic could have a material adverse effect on the Company’s business, financial condition, results of operations and growth prospects. 2. Financings 2021 Loan and Security Agreement On August 6, 2021, the Company entered into a Loan a","filed_date":"2022-05-16","accession":"0000950170-22-009942","full_text":"https://origin.rootz.global/static/filing/0000950170-22-009942.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":36,"context":"1, 2022 by the audit committee (the audit committee) of the board of directors of the Company (the Board) (Proposal 2); | | | 3. | To approve, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the proxy statement (Proposal 3); | | | 4. | To approve the amendment and restatement of the Companys amended and restated certificate of incorporation, as amended (our Charter), i","filed_date":"2022-04-27","accession":"0001193125-22-123703","full_text":"https://origin.rootz.global/static/filing/0001193125-22-123703.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":23,"context":"he genetic engineering employed in manufacturing whereas in TIL there is no further genetic engineering employed. 6 [Table of Contents](#toc_page) Background on TCRs Our strategy is to target the hallmark of genomic instability in cancer with TCRs. Genes in cancer cells can lead to the production of proteins, which are then processed by the cell into protein fragments known as peptides. These pepti","filed_date":"2022-03-30","accession":"0000950170-22-004972","full_text":"https://origin.rootz.global/static/filing/0000950170-22-004972.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"future periods, our ability to report our financial condition or results of operations could be adversely affected and may result in material misstatements of our financial statements or could have a material adverse effect on our business and trading price of our securities. • Our business, operations and clinical development plans and timelines could be adversely affected by the effects of health epidemics, inc","filed_date":"2022-03-30","accession":"0000950170-22-004972","full_text":"https://origin.rootz.global/static/filing/0000950170-22-004972.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":21,"context":"In addition, if faced with a consent solicitation or proxy contest, we may not be able to respond successfully to the contest or dispute, which would be disruptive to our business. If individuals are elected to our board of directors with a differing agenda, our ability to effectively and timely implement our strategic plan and create additional value for our stockholders may be adversely affected. The exercise of outstanding wa","filed_date":"2022-03-30","accession":"0000950170-22-004972","full_text":"https://origin.rootz.global/static/filing/0000950170-22-004972.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"tional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, which may result in material misstatements of our financial statements or could have a material adverse effect on our business and trading price of our securities.  Our cell-based therapy immuno-oncology products rely on the availability of reagents, specialized equipment, and other specialty material","filed_date":"2021-11-08","accession":"0000950170-21-003463","full_text":"https://origin.rootz.global/static/filing/0000950170-21-003463.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"tional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, which may result in material misstatements of our financial statements or could have a material adverse effect on our business and trading price of our securities.  Our cell-based and gene therapy immuno-oncology products rely on the availability of reagents, specialized equipment, and other specialty","filed_date":"2021-08-13","accession":"0000950170-21-001446","full_text":"https://origin.rootz.global/static/filing/0000950170-21-001446.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"future periods, our ability to report our financial condition or results of operations could be adversely affected and may result in material misstatements of our financial statements or could have a material adverse effect on our business and trading price of our securities. | | 3 [Table of Contents](#toc) ZIOPHARM Oncology, Inc. Table of Contents | | | | | | | | | | | | | | Page | | | | Part I - Finan","filed_date":"2021-05-06","accession":"0001193125-21-153365","full_text":"https://origin.rootz.global/static/filing/0001193125-21-153365.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":73,"context":"ependent registered public accounting firm of the Company for its fiscal year ending December 31, 2021 (Proposal 2); | | | | 3. | To approve, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the proxy statement (Proposal 3); | | | | 4. | To approve an amendment to the Companys amended and restated certificate of incorporation to increase the authorized number of share","filed_date":"2021-04-07","accession":"0001193125-21-108283","full_text":"https://origin.rootz.global/static/filing/0001193125-21-108283.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":23,"context":"oantigen-specific TCRs. The trial is designed to enroll patients with a broad range of solid tumors. The FDA has cleared the IND application submitted by the NCI for this clinical trial. However, enrollment in this clinical trial has been temporarily suspended due to issues internal to NCI and unrelated to our technology. The progress and timeline for this trial, including the timeline for dosing pat","filed_date":"2021-03-01","accession":"0001193125-21-063387","full_text":"https://origin.rootz.global/static/filing/0001193125-21-063387.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"future periods, our ability to report our financial condition or results of operations could be adversely affected and may result in material misstatements of our financial statements or could have a material adverse effect on our business and trading price of our securities. | | 6 [Table of Contents](#toc) PART I Item1. Business BUSINESS OVERVIEW We are a clinical-stage biopharmaceutical company focused on discover","filed_date":"2021-03-01","accession":"0001193125-21-063387","full_text":"https://origin.rootz.global/static/filing/0001193125-21-063387.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ional manufacturing technologies. Pursuant to the terms of the Patent License, the Company is required to pay the NCI a cash payment in the aggregate amount of $1.5million payable in $0.5million installments within sixty days, six-months, and the twelve-month anniversary of the effective date of the agreement of the Patent License. The $1.5million was paid as of the nine months ended September30, 20","filed_date":"2020-11-05","accession":"0001193125-20-286807","full_text":"https://origin.rootz.global/static/filing/0001193125-20-286807.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"tain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the COVID-19 pandemic could have a material adverse effect on the Companys business, financial condition, results of operations and growth prospects. In addition, the Company is subject to other challenges and risks specific to its business and its ability","filed_date":"2020-11-05","accession":"0001193125-20-286807","full_text":"https://origin.rootz.global/static/filing/0001193125-20-286807.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"lly to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Companys business, financial condition, results of operations and growth prospects. In addition, the Company is subject to other challenges and risks specific to its business and its ability","filed_date":"2020-08-06","accession":"0001193125-20-211865","full_text":"https://origin.rootz.global/static/filing/0001193125-20-211865.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"pant holding an Award that constitutes deferred compensation under Section 409A is a specified employee for purposes of Section 409A, no distribution or payment of any amount that is due because of a separation from service (as defined in Section 409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participants","filed_date":"2020-07-01","accession":"0001193125-20-184639","full_text":"https://origin.rootz.global/static/filing/0001193125-20-184639.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":84,"context":"ependent registered public accounting firm of the Company for its fiscal year ending December 31, 2020 (Proposal 2); | | | | 3. | To approve, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the proxy statement (Proposal 3); | | | | 4. | To approve the Companys 2020 Equity Incentive Plan (the 2020 Plan) (Proposal 4); | | | | 5. | To approve an amendment to the Comp","filed_date":"2020-05-18","accession":"0001193125-20-145086","full_text":"https://origin.rootz.global/static/filing/0001193125-20-145086.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"ional manufacturing technologies. Pursuant to the terms of the Patent License, the Company is required to pay the NCI a cash payment in the aggregate amount of $1.5million payable in $0.5million installments within sixty days, six-months, and the twelve-month anniversary of the effective date of the agreement of the Patent License. The $1.5 million was expensed in the second quarter of 2019 with $0","filed_date":"2020-05-07","accession":"0001193125-20-136200","full_text":"https://origin.rootz.global/static/filing/0001193125-20-136200.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"lly to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Companys business, financial condition, results of operations and growth prospects. In addition, the Company is subject to other challenges and risks specific to its business and its ability t","filed_date":"2020-05-07","accession":"0001193125-20-136200","full_text":"https://origin.rootz.global/static/filing/0001193125-20-136200.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"ion, or FDA, has cleared the investigational new drug, or IND, application submitted by the NCI for this clinical trial. The trial was initiated in October 2019 and preparations to enable patient enrollment by the NCI are underway. We expect the trial will enroll patients with a broad range of solid tumors over the next several years. In addition, we are currently planning a clinical program to study","filed_date":"2020-03-02","accession":"0001193125-20-058863","full_text":"https://origin.rootz.global/static/filing/0001193125-20-058863.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"on of production or distribution, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a biological product may be approved for marketing in the United States generally involves the following: | | | | completion of preclinical laborato","filed_date":"2020-03-02","accession":"0001193125-20-058863","full_text":"https://origin.rootz.global/static/filing/0001193125-20-058863.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":11,"context":"tention and resources and other factors. As of September 30, 2019, based on information readily available, there are no material matters that, in the opinion of management, are likely to result in a material adverse effect on our financial position, results of operations or cash flows. **Item 1A. Risk Factors** The following important factors could cause our actual business and financial results to differ materially f","filed_date":"2019-11-07","accession":"0001193125-19-287259","full_text":"https://origin.rootz.global/static/filing/0001193125-19-287259.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":11,"context":"management attention and resources and other factors. As of June 30, 2019, based on information readily available, there are no matters that, in the opinion of management, are likely to result in a material adverse effect on our financial position, results of operations or cash flows. **Item 1A. Risk Factors** The following important factors could cause our actual business and financial results to differ materially f","filed_date":"2019-08-08","accession":"0001193125-19-216056","full_text":"https://origin.rootz.global/static/filing/0001193125-19-216056.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":11,"context":"management attention and resources and other factors. As of March 31, 2019, based on information readily available, there are no matters that, in the opinion of management, are likely to result in a material adverse effect on our financial position, results of operations or cash flows. **Item 1A. Risk Factors** The following important factors could cause our actual business and financial results to differ materially f","filed_date":"2019-05-08","accession":"0001193125-19-141382","full_text":"https://origin.rootz.global/static/filing/0001193125-19-141382.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":85,"context":"Companys independent registered public accounting firm of the Company for its fiscal year ending December 31, 2019; | | | | 3. | To approve, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the proxy statement; | | | | 4. | To transact any other business as may properly come before the meeting or any adjournments thereof. | | These items of business are more fully de","filed_date":"2019-04-29","accession":"0001193125-19-125377","full_text":"https://origin.rootz.global/static/filing/0001193125-19-125377.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"on of production or distribution, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a biological product may be approved for marketing in the United States generally involves the following: | | | | completion of preclinical laborato","filed_date":"2019-03-05","accession":"0001193125-19-063978","full_text":"https://origin.rootz.global/static/filing/0001193125-19-063978.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":72,"context":"Companys independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018; | | | | 3. | To approve, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the proxy statement; | | | | 4. | To approve an amendment to the Companys 2012 Equity Incentive Plan, as amended, to increase the aggregate number of shares of common stock author","filed_date":"2018-08-08","accession":"0001193125-18-242868","full_text":"https://origin.rootz.global/static/filing/0001193125-18-242868.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"management attention and resources and other factors. As of June 30, 2018, based on information readily available, there are no matters that, in the opinion of management, are likely to result in a material adverse effect on our financial position, results of operations or cash flows. **Item 1A. Risk Factors** The following important factors could cause our actual business and financial results to differ materially f","filed_date":"2018-08-08","accession":"0001193125-18-242705","full_text":"https://origin.rootz.global/static/filing/0001193125-18-242705.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"management attention and resources and other factors. As of March 31, 2018, based on information readily available, there are no matters that, in the opinion of management, are likely to result in a material adverse effect on our financial position, results of operations or cash flows. **Item 1A. Risk Factors** The following important factors could cause our actual business and financial results to differ materially f","filed_date":"2018-05-10","accession":"0001193125-18-159174","full_text":"https://origin.rootz.global/static/filing/0001193125-18-159174.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TCRT","company":"Alaunos Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"first, a Phase 1/2 study for the treatment of metastatic melanoma, and the second, a Phase 2 study for the treatment of unresectable recurrent or metastatic breast cancer. We have also concluded enrollment of a single-center Phase 1b/2 study, following standard chemotherapy, for the treatment of patients with locally advanced or metastatic breast cancer. In January 2017, we announced that we paused","filed_date":"2018-03-01","accession":"0001193125-18-067077","full_text":"https://origin.rootz.global/static/filing/0001193125-18-067077.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"011adb2c9bf460c0ac826d695224c480008af9f575516dee58d330ffd6cd89d4","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"6856c83bb03f330ae71d3dfe266449ee2e50be07b1e5577ad22c9434db649e3b","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":129,"hourly_limit":500,"remaining":371,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}